China Approves ENHERTU for Second-Line HER2-Positive Gastric Cancer
China’s National Medical Products Administration (NMPA) has approved ENHERTU® (trastuzumab deruxtecan) for the treatment of adult patients with locally advanced or metastatic…
Read More...
Read More...
